Microdose is designed for three types of patients: (1) first-time GLP-1 users who want the gentlest possible introduction, (2) women who tried a higher dose elsewhere and experienced severe nausea, fatigue, or GI side effects, and (3) patients who want a slow, sustainable weight loss curve instead of rapid loss. It’s especially popular with women who are sensitive to medications or have smaller body frames.

Yes. Clinical studies of semaglutide show that even lower doses produce meaningful appetite suppression and weight loss — just at a more moderate pace than the maximum dose. Most microdose patients see a steady 1–2 pounds per week in the first few months. Your provider can also titrate you up over time if you want to accelerate results.

Same active ingredient, lower starting concentration. The boxed warning, contraindications, and safety profile are identical — the only difference is the amount of medication per dose. Microdose patients typically experience fewer and milder side effects during the first 4–8 weeks of treatment.

Absolutely. If you’re tolerating microdose well and want more aggressive results, your provider can titrate you up through the Patient Portal. Many women use microdose for the first 2–3 months to ease into treatment and then graduate to standard dosing.

Still expect some mild GI side effects — nausea, reduced appetite, occasional constipation — but at a fraction of the severity reported on full-dose GLP-1s. Most microdose patients say the side effects are easily manageable and fade within the first 2 weeks.

Expect reduced hunger within the first week. Visible weight loss usually begins by week 3–4. Because the dose is gentler, the scale may move more slowly than on full-dose semaglutide, but the trajectory is steady and sustainable.